Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment-Reference-Cited by-同舟云学术

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment

Published:2019-07 Issue: Volume:153 Page:44-51
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Nathan Steven D.,Costabel Ulrich,Albera Carlo,Behr Jürgen^ORCID,Wuyts Wim A.,Kirchgaessler Klaus-Uwe,Stauffer John L.,Morgenthien Elizabeth^ORCID,Chou Willis,Limb Susan L.,Noble Paul W.

Funder

Genentech

F. Hoffmann-La Roche

F. Hoffmann-La Roche, Ltd., Basel, Switzerland

F. Hoffmann-La Roche, Ltd

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference29 articles.

1. Idiopathic pulmonary fibrosis;Meltzer;Orphanet J. Rare Dis.,2008

2. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium;Nathan;Chest,2011

3. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis, an official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am. J. Respir. Crit. Care Med.,2011

4. Clinical course and prediction of survival in idiopathic pulmonary fibrosis;Ley;Am. J. Respir. Crit. Care Med.,2011

5. Summary of Product Characteristics - Esbriet (Pirfenidone);European Medicines Agency,2018

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cannabidiol suppresses silica-induced pulmonary inflammation and fibrosis through regulating NLRP3/TGF-β1/Smad2/3 pathway;International Immunopharmacology;2024-12

2. Identifying new molecular signatures and potential therapeutics for idiopathic pulmonary fibrosis: a network medicine approach;Mammalian Genome;2024-09-10

3. Therapeutic approaches and novel antifibrotic agents in renal fibrosis: A comprehensive review;Journal of Biochemical and Molecular Toxicology;2024-08

4. Pirfenidone use in fibrotic diseases: What do we know so far?;Immunity, Inflammation and Disease;2024-07

5. Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions;Biomedicines;2024-05-15